Progyny, Inc.
Progyny (PGNY) shares fell about 4.5% after the fertility benefits company issued weaker guidance. Q2 revenue rose to $350.5M (+5.3% YoY) and adjusted EPS was $0.55, both above estimates. But it projected $340M revenue for the next quarter, about 3% below consensus, and cut full-year revenue to $1.37B from $1.39B.
Progyny (PGNY) shares fell about 6% after its Q2 earnings. The company reported 5% sales growth, with adjusted EPS up 15% versus expectations. Q3 sales guidance calls for 7% to 11% growth and adjusted earnings are slightly lower sequentially. Gross margins rose 180 bps and covered members increased 7% to 7.2 million.
Progyny (NASDAQ:PGNY) reported Q2 CY2026 revenue of $350.5 million, up 5.3% year on year and 0.6% above analysts’ estimates. Non-GAAP EPS was $0.55, 6.2% above consensus. For next quarter, it guided revenue to $340 million, about 3% below estimates. Shares fell 10.2% to $27.08 after the release.
Over the past 7 days, alphai's AI scored 5 news stories mentioning PGNY (Progyny, Inc.). Coverage has skewed bearish: 1 bullish, 2 neutral, and 2 bearish.
Recent PGNY coverage spans earnings, insider activity and sector analysis.
In the last 30 days, PGNY insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($71K). The most active reporter was Cummings Melissa B, Chief Operating Officer, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
The sell-off is driven by weaker-than-expected forward guidance despite an earnings beat, implying traders will reprice near-term growth and margin expectations.
The earnings beat is offset by conservative Q3 sales guidance, creating near-term downside risk despite improving margins and utilization.
Beat on revenue and adjusted EPS was offset by weaker sequential guidance, driving a sharp post-earnings selloff.
The quarter shows improving profitability and cash generation alongside an active buyback, which can support near-term sentiment and valuation.
Earnings are the near-term catalyst, but the article provides no new guidance or datapoint beyond expectations and prior-quarter context.
alphai scores every news story that mentions PGNY with an AI model for sentiment and relevance, and aggregates insider trades from Progyny, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Progyny (PGNY) shares fell about 4.5% after the fertility benefits company issued weaker guidance. Q2 revenue rose to $350.5M (+5.3% YoY) and adjusted EPS was $0.55, both above estimates. But it projected $340M revenue for the next quarter, about 3% below consensus, and cut full-year revenue to $1.37B from $1.39B.
5 min readProgyny (PGNY) shares fell about 6% after its Q2 earnings. The company reported 5% sales growth, with adjusted EPS up 15% versus expectations. Q3 sales guidance calls for 7% to 11% growth and adjusted earnings are slightly lower sequentially. Gross margins rose 180 bps and covered members increased 7% to 7.2 million.
3 min readProgyny (NASDAQ:PGNY) reported Q2 CY2026 revenue of $350.5 million, up 5.3% year on year and 0.6% above analysts’ estimates. Non-GAAP EPS was $0.55, 6.2% above consensus. For next quarter, it guided revenue to $340 million, about 3% below estimates. Shares fell 10.2% to $27.08 after the release.
4 min readProgyny, Inc. (PGNY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026.htm EX-99.1 Document Progyny, Inc. Announces Second Quarter 2026 Results Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDA Robust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building Solutions V
4 min readProgyny (NASDAQ: PGNY) is set to report Q2 earnings after the market close. The article notes last quarter’s revenue of $328.5 million, up 1.4% year over year, and that guidance and EPS beat expectations. Q2 revenue is expected to rise 4.7% y/y. Analysts have largely reconfirmed estimates; average price target is $34 vs $31.66.
3 min readBiotech stocks hit 52-week highs on July 14, 2026. Hemab Therapeutics (COAG) reached $42.03 after positive Phase 2 results for HMB-002 and launched HMB-003. Alamar Biosciences (ALMR) hit $29.43 on a U.S. university proteomics partnership. Progyny (PGNY) rose 4% to $32; 2026 revenue guidance $1.365B-$1.405B. 10x Genomics (TXG) closed $43.98; 2026 revenue $600M-$625M. Viemed (VMD) peaked $12.61; 2026 net revenue $312M-$320M.
5 min readProgyny (PGNY) shares rose 3.5% to $31.73 after KeyBanc raised its price target to $35 from $30 and kept an Overweight rating, citing expectations for a strong earnings report and higher future guidance. The article also notes other bullish analyst actions, including Truist raising its target and Canaccord upgrading to Buy.
4 min readLivingston Mark S. (CHIEF FINANCIAL OFFICER) sold 599 shares of Progyny, Inc. (PGNY) at $25.50 on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min readLivingston Mark S. (CHIEF FINANCIAL OFFICER) sold 1,918 shares of Progyny, Inc. (PGNY) at $25.50 on 2026-06-04 under a Rule 10b5-1 trading plan.
1 min readSwartz Allison (EVP, GC) sold 599 shares of Progyny, Inc. (PGNY) at $25.08 on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min read
